Dynamic Contrast-Enhanced MR Imaging in Head and Neck Cancer: Techniques and Clinical Applications

S. Gaddikeri, R.S. Gaddikeri, T. Tailor and Y. Anzai

doi: https://doi.org/10.3174/ajnr.A4458
http://www.ajnr.org/content/37/4/588

This information is current as of March 26, 2024.
ABSTRACT

SUMMARY: In the past decade, dynamic contrast-enhanced MR imaging has had an increasing role in assessing the microvascular characteristics of various tumors, including head and neck cancer. Dynamic contrast-enhanced MR imaging allows noninvasive assessment of permeability and blood flow, both important features of tumor hypoxia, which is a marker for treatment resistance for head and neck cancer. Dynamic contrast-enhanced MR imaging has the potential to identify early locoregional recurrence, differentiate metastatic lymph nodes from normal nodes, and predict tumor response to treatment and treatment monitoring in patients with head and neck cancer. Quantitative analysis is in its early stage and standardization and refinement of technique are essential. In this article, we review the techniques of dynamic contrast-enhanced MR imaging data acquisition, analytic methods, current limitations, and clinical applications in head and neck cancer.

ABBREVIATIONS: AIF = arterial input function; DCE–MR imaging = dynamic contrast-enhanced MR imaging; EES = extracellular extravascular space; GCA = gadolinium contrast agent; HNC = head and neck cancer; \( K_{\text{ep}} \) = transfer function from EES to the plasma space; \( K \text{trans} \) = volume transfer constant; \( V_e \) = extracellular extracellular volume fraction

Head and neck cancer (HNC) accounted for approximately 3% of all new cancers and 2% of all cancer-related deaths in 2010 in the United States.¹ Conventional cross-sectional imaging (CT and MR imaging) plays an important role in assessing locoregional extension of a primary tumor and gross nodal metastases. The shortcomings of conventional imaging include failure to identify early locoregional recurrence, detection of nodal metastasis in normal-sized lymph nodes, prediction of tumor response to treatment, and treatment monitoring in patients with HNC. CT perfusion has been reported to provide vascular information about HNC, though there is increasing concern for exposure to ionizing radiation.² FDG-PET is also widely used for initial staging and monitoring response to treatment. However, there is increasing restriction in the number of FDG-PET scans that any patient can undergo during the entire treatment course.³

Dynamic contrast-enhanced MR imaging (DCE–MR imaging) is an imaging technique in which rapid sequential MR images are obtained through an area of interest before, during, and after a bolus administration of contrast material. This process allows quantification of various vascular biomarkers, such as blood volume, blood flow, permeability, and wash-in and washout properties.

Angiogenesis (formation of new vessels) is one of the hallmarks of cancer because it is necessary for tumor survival and growth. This process of neoangiogenesis results in tortuous and leaky vessels because the vessel walls in tumor may be discontinuous.⁴ Characteristics of tumor microvasculature include lack of muscularis propria, widened interendothelial junctions, and a discontinuous or absent basement membrane, all of which contribute to increased permeability.⁵ It has been reported that the degree of angiogenesis in a tumor correlates well with tumor biology.⁵,⁶ Well-differentiated tumors may have near-normal microvasculature, whereas poorly differentiated tumors have disorganized and leaky vessels.⁵ The leaky blood vessels are inefficient in the delivery of oxygen, thus potentially contributing to tumor hypoxia. The process of gadolinium leakage from intravascular-to-extravascular compartments depends on multiple factors such as blood flow to tissue, microvascular attenuation, vascular permeability, and fractional volume of extracellular extravascular space (EES).⁷ These biologic features can be assessed by DCE–MR imaging.

In this article, we review the technical considerations of DCE–MR imaging, qualitative and quantitative analysis, and potential clinical applications in HNC.
Technique

Basic Principles of DCE–MR Imaging. Following intravenous administration, gadolinium contrast agent (GCA) travels through the microvasculature and leaks from the intravascular compartment to the EES by passive diffusion, altering signal intensity of the tissue by changing the relaxation rates of water protons. The changes in relaxation and signal depend on how GCA distributes within the tissues. The transfer function from plasma to EES is commonly referred to as volume transfer constant ($K_{\text{trans}}$) (Fig 1).

As the concentration of intravascular GCA decreases, GCA starts moving from the EES back into the plasma space. The transfer function from EES to the plasma space is referred to as ($K_{\text{ep}}$) (Fig 1). DCE–MR imaging uses rapid T1-weighted imaging to measure the relaxivity changes resulting from gadolinium leakage in and out of the EES. The T1-relaxation is generally assumed to be proportional to the degree of concentration of GCA in the EES. The time-concentration curve often reveals the dynamics of GCA accumulation and washout across time. With the knowledge of concentration of GCA (signal intensity) in the EES and vascular compartment (arterial input function [AIF]) with time, DCE MR imaging allows quantitative assessment of vascular function in HNC.

Data Acquisition

The DCE-MR image acquisition consists of 3 steps: 1) a baseline T1 mapping before administration of GCA, 2) dynamic data acquisition, and 3) arterial input function assessment.

Baseline T1 Mapping. To obtain accurate kinetic fitting of DCE–MR imaging data, T1 mapping is critical. The basic assumption for pharmacokinetic modeling of DCE–MR imaging data is that tissue T1 relaxivity (and hence the signal intensity of tissue) at each time point is directly proportional to the tissue concentration of GCA. However, this relationship is not always linear because it is influenced by the T1 characteristics of the native tissue. To compensate for this nonlinear relationship between signal intensity and tissue GCA concentration, baseline T1 mapping and equilibrium magnetization at each imaging time point are essential. The T1 values calculated on a voxel-by-voxel basis are termed the $T_{10}$ map.

Dynamic Data Acquisition. The dynamic data acquisition follows immediately after baseline T1 mapping. The images are acquired before, during, and after intravenous gadolinium administration. The critical component of high-quality DCE–MR imaging is high

![Flow chart demonstrating a typical quantitative method of data analysis.](https://example.com/flow_chart.png)

**FIG 1.** Flow chart demonstrating a typical quantitative method of data analysis. The information from the T1 mapping and dynamic data is used to estimate the changes in T1 relaxivity during the dynamic scan, which, in turn, provides the information of tissue gadolinium concentration. By fitting the tissue gadolinium concentration and arterial input function data in to commonly used “2-compartment” models (extended Toft or adjusted Brix model), various parameters can be assessed. The difference between the Toft and extended Toft model is the inclusion of assessment of blood plasma volume per unit tissue volume in the later version.
temporal resolution (2–4 seconds). This allows accurate assessment of the hemodynamic process as GCA passes through the microvasculature in the tissue of interest. Higher temporal resolution may compromise SNR and/or coverage (number of sections). The trade-offs among temporal resolution, SNR, and spatial resolution need to be carefully balanced because a reasonable SNR and spatial resolution (in-plane resolution, 0.5–1.7 mm) are required for adequate assessment of tumor vascular function. The dynamic sequence can be tailored depending on the planned method for data analysis. For example, high spatial resolution with reasonable temporal resolution imaging is sufficient for a “semiquantitative” time-intensity curve analysis, whereas a very high temporal resolution with reasonable spatial resolution is critical for “quantitative” kinetic analysis.

The application of DCE–MR imaging has been reported with both 1.5T and 3T scanners. Various types of fast 2D and 3D T1-weighted sequences have been described, including fast spin-echo T1WI, FISP or 3D-T1WI FSPGR, 3D-T1WI FLASH, and turbo FLASH. Application of parallel imaging for DCE–MR imaging has increased temporal resolution by severalfold, and thus fast 3D acquisitions are gradually replacing 2D acquisitions in DCE–MR imaging. Details of the dynamic sequence practiced at the University of Washington are summarized in Table 1.

The arterial input function. Another crucial component of DCE–MR imaging is the assessment of an AIF. The AIF estimates the rate of change in the concentration of contrast in the plasma (vascular space) with time. An accurate AIF is essential for quantitative analysis of dynamic data by using any of the currently available analytic methods. Generally, AIF is commonly obtained from the dynamic dataset. Any visible large artery within an area of interest can be selected for AIF with the dynamic dataset. For HNC imaging with DCE–MR imaging, the carotid and vertebral arteries are well-suited for AIF selection because they run along the long axis of the neck and are of relatively large caliber.

### Table 1: Dynamic sequence at the University of Washington is performed on a 3T scanner

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Philips</th>
<th>Siemens</th>
<th>GE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coil</td>
<td>SENSE</td>
<td>iPAT</td>
<td>ASSET</td>
</tr>
<tr>
<td>Parallel imaging</td>
<td>3D-T1WI FFE</td>
<td>3D-T1WI FSPGR</td>
<td></td>
</tr>
<tr>
<td>Sequence</td>
<td>3D-T1WI FSPGR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TR/TE for TI mapping</td>
<td>5.2/2.5 ms</td>
<td>12°, 20°, 15°, 10°, and 2°</td>
<td></td>
</tr>
<tr>
<td>MFA for TI mapping</td>
<td>12°, 20°, 15°, 10°, and 2°</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TR/TE/FA for dynamic imaging</td>
<td>5.2/2.5 ms/5°</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOV</td>
<td>212 × 149 mm²</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voxel</td>
<td>95/0.95/3.00 mm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Section thickness</td>
<td>3 mm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Signal averaging</td>
<td>N/A:1</td>
<td>ACQ: 1</td>
<td>NEX: 1</td>
</tr>
<tr>
<td>Number of sections per dynamic scan</td>
<td>20/Axial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>section orientation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Temporal resolution</td>
<td>3.6 seconds</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total TI mapping acquisition time</td>
<td>26.5 seconds</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total dynamic acquisition time</td>
<td>6.10 minutes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fat saturation</td>
<td>No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contrast injection</td>
<td>Single dose of 20-mL gadoteridol (ProHance) injected at a rate of 5 mL/s through a peripheral arm vein, followed by a 20-mL saline flush with a power injector</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 2: Commonly used model-free (semiquantitative) parameters for DCE-MRI analysis

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Definition</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Area under curve</td>
<td>Area under the signal intensity or gadolinium dynamic curve</td>
<td>a.u.min or mmol.min/L</td>
</tr>
<tr>
<td>Relative signal intensity</td>
<td>$S_t/S_0$</td>
<td>NA</td>
</tr>
<tr>
<td>Initial slope or enhancement slope/rate</td>
<td>Maximum or average slope in the initial enhancement</td>
<td>a.u./min</td>
</tr>
<tr>
<td>Washout slope/rate</td>
<td>Maximum or average slope in the washout phase</td>
<td>a.u./min</td>
</tr>
<tr>
<td>Peak enhancement ratio or maximum signal enhancement ratio</td>
<td>$(S_{max} - S_0)/S_0$</td>
<td>NA</td>
</tr>
<tr>
<td>$T_{max}$ or time to peak</td>
<td>Time from contrast arrival to peak</td>
<td>$S^{-1}$</td>
</tr>
<tr>
<td>Maximum intensity–time ratio</td>
<td>PER/$T_{max}$</td>
<td>$S^{-1}$</td>
</tr>
</tbody>
</table>

### Notes
- FFE indicates fast-field echo; FSPGR, fast-spoiled gradient recalled; MFA, multiple flip angles; SENSE, sensitivity encoding; iPAT, integrated parallel acquisition technique; ASSET, array spatial sensitivity encoding technique; NSA, number of signal averages; ACQ, acquisitions; FA, flip angle.
- Siemens, Erlangen, Germany.
- GE Healthcare, Milwaukee, Wisconsin.
- Philips Healthcare, Best, the Netherlands.
- Bracco Diagnostics, Princeton, New Jersey.
Data Analysis

DCE–MR imaging is commonly analyzed with semiquantitative analysis or quantitative analysis.

Semiquantitative Method

The semiquantitative method is a model-free analysis by using the observed data points on a time-intensity curve. It is a simple and easily implementable method by using commercially available software. Commonly calculated parameters on the time-intensity curve are listed in Table 2. The time-intensity curve obtained following placement of an ROI on the tumor provides a rough estimate of how fast the GCA enters and exits the tumor. It has been reported that malignant tumors have a longer time to peak and lower relative maximum enhancement compared with benign lesions in the head and neck. The prolonged time to peak and lower relative maximum enhancement were also noted in metastatic lymph nodes compared with benign lymph nodes among patients with HNC. The limitation of this semiquantitative analysis is that the semiquantitative parameters do not necessarily have physical correlates; rather, they may represent mixed measures. For example, the area under curve is a combination of tissue blood flow vascular permeability and fractional interstitial space and is, therefore, not an accurate estimate of blood volume. Therefore, the physiologic meanings of these parameters remain ambiguous as to what biologic property they represent.

Quantitative Methods

Quantitative analysis of DCE–MR imaging data is based on the generalized pharmacokinetic models. The 2 most important assumptions of these models are the following: 1) GCA is distributed in ≥1 compartment of the human body, and 2) distribution of the contrast agent in a particular compartment is uniform.

A typical quantitative method of data analysis is outlined in the flow chart (Fig 1). The most frequently used pharmacokinetic models in head and neck DCE–MR imaging data analysis include the Toft and Kermode model (Toft model), the Brix model, and their modifications (Fig 1). These are based on the assumption of a “2-compartment model,” in which the GCA is distributed into the “central” and “peripheral” compartments. The central compartment consists of intravascular extracellular volume fraction (blood plasma), and the peripheral compartment consists of extravascular extracellular volume fraction. The Toft model generally requires the knowledge of AIF and T1 mapping for accurate assessment of quantitative parameters. Fitting the DCE–MR imaging data into 1 of these models allows estimation of various model-base parameters, which potentially aids in the understanding of tumor physiol-
ogy and pathology. Frequently used parameters that can be obtained from quantitative DCE–MR imaging data are summarized in Table 3.

Quantitative methods of data analysis provide parameters quantifying microvasculature physiology and tumor biology. Additionally, the model-based parameters are more precise and reproducible and are reported to be independent of scanners and tissue type. Hence, these parameters may be potentially useful for sequential follow-up to determine treatment response in an individual patient and also as biologic markers for predicting and monitoring the therapeutic efficacy in multicenter trials.

Clinical Applications of DCE–MR Imaging in Head and Neck Cancer

One of the most exciting aspects of DCE–MR imaging application in HNC is its potential to serve as an imaging biomarker for hypoxia. The abnormal tumor vessels are inefficient in delivering oxygen or chemotherapy drugs to the tissue. In addition, this inefficiency causes increased interstitial fluid pressure, which ultimately reduces tumor perfusion, further facilitating tumor hypoxia. Although a study by Newbold indicated that tumors with higher \( K^{\text{trans}} \) were associated with hypoxia defined by pimonidazole and carbonic anhydrase staining, and hence poor outcome, others reported that tumors with lower \( K^{\text{trans}} \) were associated with poor response. \( K^{\text{trans}} \) generally reflects a combination of perfusion and permeability. Lower \( K_{\text{ep}} \) is also reported to correlate with poor response to treatment. A tumor with higher \( K^{\text{trans}} \), highly perfused tumor has higher oxygenation, better delivery of chemotherapeutic drugs, likely explaining improved treatment response. Skewness of \( K^{\text{trans}} \) is also reported to predict treatment response, that a tumor with larger skewed \( K^{\text{trans}} \) has a worse prognosis potentially reflecting tumor heterogeneity.

DCE–MR imaging has been reported to be useful for various applications in HNC imaging, such as differentiating squamous cell carcinoma from lymphoma and undifferentiated carcinomas, detecting metastatic lymph nodes, assessing tumor cell proliferation and microvessel attenuation, and predicting early treatment response and treatment outcome.

We searched MEDLINE, PubMed, and Google for the literature published during the most recent 6-year interval (2008–2013) containing all of the following: DCE–MR imaging, HNC, and quantitative (model-based) analysis of dynamic data for pretreatment assessment and/or monitoring treatment response. The Online Table summarizes various studies in the literature and their respective contributions to DCE–MR imaging of HNC by using various quantitative methods. Early assessment of treatment response is critical for advanced head and neck cancers. The question remains as to whether pretreatment measures of DCE parameters suffice to address the treatment response or it is necessary to measure changes in DCE parameters to assess treatment response.

Challenges

DCE–MR imaging of HNC is clearly in its early stage. Substantial variability exists in quantification methods, parameter choice,
and analytic methods. Many factors in the data acquisition and analysis can affect the reliability of results in DCE–MR imaging studies. For example, the accuracy and precision of the pharmacokinetic parameter estimates are largely determined by SNR, temporal resolution of the MR image, AIF, and estimation of T1 mapping. Systematic errors can be introduced from various sources, such as the breakdown of linearity in the gadolinium concentration calibration curve and inaccuracy of T1 mapping.

Standardization of data acquisition and analysis will facilitate the translation of DCE–MR imaging to clinical settings, in particular to multicenter clinical trials. The DCE–MR imaging subcommittee of the Radiological Society of North America Quantitative Imaging Biomarkers Alliance initiative provides guidelines for data acquisition, analysis, and quality control on 1.5T systems. The image intensity should be converted to gadolinium concentration through the use of a multiple flip angle precontrast T1 map after corrections for patient motion, B1 field inhomogeneity, and coil sensitivity. The pharmacokinetic parameter $K_{trans}$ (Toft model) and area under curve (model-free parameter) are recommended as standard quantitative end points that should be used in clinical trials and practice.

Another challenge with DCE–MR imaging parameters is validation with tumor histology and hypoxia. A potential reason includes tumor heterogeneity at the subvoxel level. Therefore, some authors suggest that DCE–MR imaging parameters may be better validated with immunohistochimical measurements averaged over several fields randomly picked from the ROI.

**CONCLUSIONS**

Although DCE–MR imaging has the potential to provide biologic information of tumor angiogenesis and vascular function in HNC, its technical development is still in an early stage. The standardization of image acquisition and data analysis is critical to moving forward with a multicenter head and neck tumor registry and in determining the clinical role of DCE–MR imaging in head and neck oncologic imaging.

Disclosures: Tina Tailor—RELATED: Grant: American Society of Head and Neck Radiology, William N. Hanafee Award

**REFERENCES**


